Dilept
What is it?
An experimental neurotensin-related peptidomimetic also called GZR-123. Its environmental-stress source is linked below; clinical effectiveness is not established.
Identity / background source ↗
Research context
An experimental neurotensin-related peptidomimetic (GZR-123), included in the 2007 environmental-chamber comparison.
- Working classification
- Environmental nootropic research
- Research collection
- Related nootropics & combinations · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Shared environmental comparison; not independent replication
- Study methods
- —Small groups, historical controls and unresolved allocation
- Independent replication
- —Possible overlap with the Academy report
- Source access
- —Original Russian journal PDF; selected methods checked
- Safety evidence
- —Human long-term safety and operational protection not established
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Linked sources
Explore the research map and unresolved leads ↗
Meteoadaptogenic properties of peptide drugs in healthy volunteers
Format: Original journal PDF · Reviewed: Methods and selected tables; encoding limits
P. D. Shabanov, V. P. Ganapolsky, P. V. Aleksandrov · Eksp Klin Farmakol. 70(6):41–47
Cold, heat and simulated altitude experiments compared four preparations, placebo and historical no-drug measurements. Effects varied by compound and endpoint.
- Population / setting
- 127 healthy men aged 20–24 across a three-day environmental programme; active groups reported as 10–20, placebo 8–10 per stage
- What was checked
- Publisher PDF methods and selected tables checked. Cyrillic text encoding limits numerical transcription; full table-level verification remains incomplete.
Limitations & review scope
- Random allocation and blinding not established; historical controls and baseline differences limit attribution.
- Exact arm-by-environment denominators remain unresolved; 127 is the programme total, not Noopept enrollment.
- Experimental intranasal peptide preparations are not equivalent to marketed oral products.
- No validated protection from heat illness, operational accidents or long-term harm.
- Possible overlap with the Academy report; do not count as independent replication.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.